Development and optimization of a nanoparticle-based targeted drug delivery system for oral anticancer therapy using natural polymer–drug conjugates

Project Abstract

This study reports the design, synthesis, and optimization of a nanoparticle-based targeted drug delivery system for oral anticancer therapy using natural polymer–drug conjugates to enhance bioavailability, tumor targeting, and therapeutic efficacy while minimizing systemic toxicity. A biodegradable natural polymer (e.g., chitosan or alginate) was chemically conjugated with a selected hydrophobic chemotherapeutic agent via a linker sensitive to tumor-associated conditions (pH, enzymes) to form a polymer–drug conjugate that self-assembles into nanoparticles in aqueous media. The nanoparticle formulation was engineered to achieve a particle size range of 100–180 nm, a near-neutral surface charge, and high drug loading efficiency, optimized through a design of experiments (DoE) approach evaluating polymer degree of substitution, linker type, solvent system, and cross-linking density. Surface functionalization with a targeting ligand (such as folic acid or transferrin) facilitated receptor-mediated endocytosis by cancer cells overexpressing corresponding receptors, while PEGylation was employed to improve mucus penetration and circulatory stability in the gastrointestinal tract. In vitro studies demonstrated controlled, pH-responsive drug release with accelerated release under acidic tumor-mimicking conditions and minimal leakage at physiological pH. Cellular uptake assays using cancer cell lines (e.g., HCT-116, MCF-7) confirmed enhanced internalization of targeted nanoparticles compared with non-targeted controls, accompanied by increased cytotoxicity in a dose- and time-dependent manner. Mechanistic analyses indicated induction of apoptosis via mitochondrial pathways, G1 cell cycle arrest, and downregulation of pro-survival signaling, with reduced off-target effects on normal epithelial cells. The system’s oral administration feasibility was evaluated using simulated gastric and intestinal fluids, indicating nanoparticle stability and preserved drug activity across transit with protective polymeric matrices mitigating proteolytic degradation. In vivo pharmacokinetic and biodistribution studies in appropriate xenograft models revealed superior oral bioavailability and preferential accumulation of the nanoparticle payload within tumor tissue compared with free drug, correlating with improved tumor growth inhibition and extended survival in treated cohorts. Comprehensive toxicity profiling showed reduced hematological, hepatic, and renal adverse effects relative to conventional therapy, supporting a favorable therapeutic index. Advanced imaging and histopathological evaluation corroborated targeted delivery and minimal systemic toxicity. The study also explored scalable synthesis, reproducibility, and long-term stability under accelerated aging conditions, establishing process parameters suitable for potential translational development. The results demonstrate that natural polymer–drug conjugate–based nanoparticles can combine the advantages of biodegradability, biocompatibility, and targeted delivery to overcome oral administration barriers and to achieve efficient, site-specific anticancer activity. Limitations related to large-scale manufacturing, immunogenic potential of natural polymers, and interpatient variability in receptor expression are discussed, alongside strategies to address these challenges through robust quality-by-design frameworks and personalized medicine approaches. This work lays a foundation for clinically translatable oral nanomedicine platforms that strategically exploit tumor microenvironment cues and receptor-mediated uptake to maximize therapeutic outcomes while reducing systemic toxicity.

Project Overview

What This Project Is About

---

A simple exploration of how tiny particles can carry cancer drugs inside the body to target tumors more precisely, using natural materials that can safely break down in the body. The project looks at making these drug carriers (nanoparticles) that can deliver drugs when swallowed, and how to optimize them to work better and with fewer side effects.

---

---

The Problem It Addresses

---

Cancer drugs often affect healthy tissues and can cause severe side effects. Traditional oral delivery can also lead to poor drug absorption and inconsistent dosing. This project seeks safer, more effective delivery by using natural polymers to shield the drug and release it mainly at tumor sites.

---

---

Objectives of the Project

---

1. Understand how nanoparticle carriers are built from natural materials.
2. Evaluate how the carrier releases the drug in conditions similar to the body and inside tumors.
3. Study how well the system is absorbed when taken orally and reaches the target site.
4. Identify potential safety issues and how to minimize them.
5. Propose an optimized formulation with better stability and effectiveness.

---

---

What You Will Do Step by Step

---

Review literature on natural polymers and drug conjugates; design a model nanoparticle; prepare and characterize samples (size, stability, drug loading); test drug release in simulated body fluids; assess oral uptake using simple lab models; analyze data to compare formulations; write up findings with practical recommendations.

---

---

Expected Outcome

An improved, safe nanoparticle formulation for oral anticancer therapy with demonstrated controlled drug release and better targeting potential, along with practical guidelines for future development.